Sana Biotechnology (NASDAQ:SANA) Trading Up 12.2% – What’s Next?

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) were up 12.2% during trading on Monday . The company traded as high as $2.59 and last traded at $2.58. Approximately 627,046 shares traded hands during trading, a decline of 70% from the average daily volume of 2,119,753 shares. The stock had previously closed at $2.30.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on SANA shares. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Sana Biotechnology in a report on Wednesday, November 27th. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th.

Sana Biotechnology Stock Down 5.6 %

The firm has a market cap of $522.45 million, a price-to-earnings ratio of -1.68 and a beta of 1.33. The business has a 50 day moving average price of $3.28 and a 200-day moving average price of $4.80.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. Research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This trade represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 31.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SANA. FMR LLC lifted its position in shares of Sana Biotechnology by 16.3% during the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after purchasing an additional 4,438,949 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Sana Biotechnology by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after buying an additional 276,055 shares during the last quarter. State Street Corp grew its position in shares of Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after acquiring an additional 269,274 shares in the last quarter. Integral Health Asset Management LLC increased its holdings in shares of Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after acquiring an additional 220,000 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Sana Biotechnology by 126.6% during the 3rd quarter. Barclays PLC now owns 318,910 shares of the company’s stock valued at $1,325,000 after acquiring an additional 178,179 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.